FY2025 · ended Dec 31, 2025 · Revenue $4.71B, +6.2% YoY · Filed Feb 24, 2026
Elanco Animal Health Incorporated (ELAN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.7 billion and a net loss of $232.0 million. Free cash flow was $284.0 million. As of Jun 30, 2026 it held $530.0 million in cash and investments and $3.9 billion in total debt.
Revenue (TTM)
$5.02B
+12.0% vs year-ago TTM
Net income (TTM)
$-199.00M
-145.9% vs year-ago TTM
Operating cash flow (TTM)
$617.00M
+7.9% vs year-ago TTM
Free cash flow (TTM)
$379.00M
+5.0% vs year-ago TTM
EPS (TTM)
$-0.40
-145.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
497.17M
+0.5% vs prior year
Net cash
$-3.39B
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELAN (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Indianapolis, IN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1739104
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.7B | $4.4B | $4.4B | $4.4B | $4.8B |
| Net income | -$232.0M | $338.0M | -$1.2B | -$78.0M | -$483.0M |
| Diluted EPS | -$0.47 | $0.68 | -$2.50 | -$0.16 | -$0.99 |
| Operating cash flow | $560.0M | $541.0M | $271.0M | $452.0M | $483.0M |
| Free cash flow | $284.0M | $394.0M | $131.0M | $281.0M | $324.0M |
| Total assets | $13.4B | $12.6B | $14.4B | $15.5B | $16.5B |
| Total liabilities | $6.8B | $6.5B | $8.1B | $8.2B | $9.0B |
| Stockholders' equity | $6.5B | $6.1B | $6.2B | $7.3B | $7.5B |
| Cash and investments | $545.0M | $468.0M | $352.0M | $345.0M | $638.0M |
| Total debt | $4.1B | $4.4B | $5.9B | $6.0B | $6.5B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 27, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| 10-K | Annual report | Feb 24, 2026 | Dec 31, 2025 |
All 1015 Elanco Animal Health Incorporated SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.